3 results
Primary: To demonstrate the efficacy of QGE031 relative to placebo at 12 weeks in patients withatopic dermatitis (AD) as assessed by Eczema Area and Severity Index (EASI).Secondary: efficacy assessed by Investigator Global Assessment (IGA, 12 weeks…
Target Population:Subjects with urinary incontinence (UI) caused by neurogenic detrusor overactivity (NDO)due to either spinal cord injury (SCI) or multiple sclerosis (MS), who have not beenadequately managed with oral medication and who routinely…
To assess the safety, tolerability, pharmacodynamics and efficacy of two DLQ02 topical formulations in patients with plaque psoriasis. To assess systemic exposure of CsA and F6H8 after topical application.